research report · PG

Procter & Gamble Co

Johannes Vermeer, Woman Holding a Balance, c. 1664, detail · National Gallery of Art

Viridis’s deep research report, written Nov 1, 2026 from its quarterly report (10-Q for the quarter ended Sep 30, 2026, filed Oct 22, 2026). Written and checked with Anthropic’s Claude models.

your email, no card; what you get

business trajectory

Mixed

material evidence both ways

financial resilience

Strong

can meet its obligations and fund its plan for two years with money it can count on, with room

Judgments of the business from its filings, not of its shares: no valuation, no advice.

bottom line

P&G's sales have recovered but its profits have not. In the first quarter of fiscal 2027 (July–September 2026), organic sales grew 4.0%, led by 2.4% volume growth. Over the same quarter gross margin fell 160 basis points to 49.8%, and core EPS excluding currency was flat. Management kept its core EPS growth range at 0–3% while raising its expected after-tax headwind from costs, interest and currency to $0.79 per share, and said the larger commodity hit lands in the second quarter and second half. Cash generation funds the dividend comfortably, so the question for the year is margin, not solvency.

what changed this quarter

  • Net sales were $23.3B, up 4.0%. Organic sales rose 4.0%: volume +2.4%, mix +1.1%, price +0.4%.
  • Operating income rose 1% to $5.94B, and operating margin fell to 25.5% from 26.2%. Diluted EPS was $1.97 against $1.95; core EPS was $2.00 against $1.99.
  • Guidance:
  • Kept: organic growth of 1–3% and core EPS growth of 0–3% ($6.89–$7.11).
  • Updated for Thorne: all-in sales growth of 2–4%.
  • Raised: the cost headwind, to $0.79 per share from 56 cents in July, per the call.
  • Thorne, a supplements brand, was acquired on October 1 for $3.9B in cash. The company ties the quarter's net debt increase to the deal; it included $5.8B of net new short-term borrowing.
  • Debt due within one year rose to $17.0B from $11.3B at June 30. Cash was $15.4B.

in the full report

Its findings, each with the evidence, the strongest counterpoint and what would prove it wrong:

  • The volume recovery is broad, but part of it is pulled forward or bought with price
  • Margins are paying for the recovery, and the costliest quarters are ahead
  • Earnings growth is stuck below P&G's own long-term target
  • Thorne and buybacks are being funded with more expensive debt

Then its finances, the quality of its earnings, its management, the case for and against, and what to watch, its claims cited to the filings and checked against them.

read it whole

Your email and the code we send it, no card. The report then opens: a free account has 2 free reports a month from the library, the reports already written. Already have a Viridis account? Use its email, and the report goes on it. You also see what PG files, free: its deadlines and its red flags.

Subscribe: your plan’s reports work on any company that files with the SEC, written for you if nobody has asked yet, and each new one on the companies you choose comes as they file.

In Claude or ChatGPT, ask: “What does Viridis's report on PG say?” Add Viridis to Claude, or to ChatGPT.